Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

• Published in: The New England journal of medicine Vol. 365; no. 23; pp. 2155 - 2166
• Main Authors: Sterling, Timothy R, Villarino, M. Elsa, Borisov, Andrey S, Shang, Nong, Gordin, Fred, Bliven-Sizemore, Erin, Hackman, Judith, Hamilton, Carol Dukes, Menzies, Dick, Kerrigan, Amy, Weis, Stephen E, Weiner, Marc, Wing, Diane, Conde, Marcus B, Bozeman, Lorna, Horsburgh, C. Robert, Chaisson, Richard E
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 08.12.2011
• Subjects: Adult; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antitubercular Agents - administration & dosage; Antitubercular Agents - adverse effects; Bacterial diseases; Biological and medical sciences; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; General aspects; Hepatotoxicity; HIV; Human bacterial diseases; Human immunodeficiency virus; Humans; Infections; Infectious diseases; Intention to Treat Analysis; Isoniazid; Isoniazid - administration & dosage; Isoniazid - adverse effects; Male; Medical sciences; Middle Aged; Motivation; Pharmacology. Drug treatments; Prospective Studies; Rifampin - administration & dosage; Rifampin - adverse effects; Rifampin - analogs & derivatives; Risk Factors; Self Administration; Skin; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis - epidemiology; Tuberculosis - prevention & control; Tuberculosis and atypical mycobacterial infections; Virus Latency; Infection; Medicine; Antituberculous agent; Antibacterial agent; Isoniazid; Rifapentine
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1104875

Treatment of latent TB is an important public-health strategy, but 9 months of daily isoniazid (270 doses) poses challenges for compliance. In this study, 3 months of weekly isoniazid plus rifapentine (12 doses) was found to be noninferior to 9 months of isoniazid alone. Tuberculosis results in near...